Rare cancers, when taken all together, make up an estimated 20 to 25 percent of all cancers diagnosed. With more than 1.7 million people in the U.S. expected to be diagnosed with cancer this year, that could mean as many as 400,000 people will learn they have a rare cancer. Often, these patients have few treatment options.Read More
Since 2011, immunotherapy has emerged as an exciting new approach to cancer treatment that is yielding unprecedented, durable responses for patients with an increasingly diverse array of cancer types. Much …Read More
Building on advances in technology and analytical tools, real-world data (RWD) sources have attracted increasing interest as means to efficiently answer important clinical, research, and regulatory questions around oncology treatments and outcomes. RWD can come from a variety of sources, including medical claims data, electronic health records, patient-reported outcomes, and product or disease registry data. Real-world evidence (RWE) is clinical evidence generated from these data.
While the randomized controlled trial remains the gold standard for gathering clinical evidence for regulatory use, RWE can provide critical insights in situations where such trials may be difficult to complete. This is especially relevant in oncology, where personalized medicine approaches are leading to increasingly smaller patient populations that necessitate new strategies for efficient drug development.Read More
Every two minutes, a woman somewhere in the world dies of cervical cancer.
That harrowing statistic, shared by Anna R. Giuliano, PhD, founding director of the Center for Immunization and Infection Research in Cancer at the Moffitt Cancer Center in Tampa, Florida, reflects a great frustration in public health. There is a vaccine that prevents infection with the virus that can cause cervical cancer and several other cancer types, yet worldwide, not enough people are taking advantage of it.Read More
Every person who hears the words “you have cancer” has a unique story. As part of Cancer Today’s mission to provide “practical hope” and “real knowledge” to those who are affected by cancer, we strive to highlight those stories to provide a real-life glimpse into the challenges of treatment and what comes after.
As National Cancer Survivor Month comes to a close, we’d like to take an opportunity to reflect on some of the lessons we’ve learned from the cancer survivors who have shared their stories with Cancer Today, the magazine and online resource for cancer patients, survivors, and caregivers, which is published by the American Association for Cancer Research.Read More
When I started my postdoc at Georgetown University’s Lombardi Comprehensive Cancer Center in May 2016, I was thrilled to experience a truly comprehensive training in breast cancer. During my tenure, I decided to take advantage of opportunities offered to me outside of the lab to learn about cancer from every angle, including attending weekly breast tumor boards and presenting my work to the Georgetown Breast Cancer Advocates (GBCA).
I’ll never forget at the end of my presentation with GBCA, one of the advocates, Jamie, asked what the side effects were for a new treatment I was proposing. I was proud that I had done some research on this and confidently stated, “they are the same as tamoxifen,” a commonly used breast cancer treatment.Read More
Decades of research have led to the identification of an increasing number of cancer-causing substances in our environment. These substances, known as environmental carcinogens, can be found anywhere, including in our air, water, food, and workplace.
Despite the progress we have made in identifying and increasing awareness of such carcinogens, experts believe that we have a long way to go before we have fully delineated them and successfully regulated our exposures to reduce cancer incidence. Therefore, establishing methods to better identify all of the carcinogens in our environment, to measure our exposure to them, and to prevent cancer caused by them are areas of active investigation in the field.Read More
Back for the month of June are the editors’ picks from the eight scientific journals published by the American Association for Cancer Research (AACR). Selections this month range from the identification of a long noncoding RNA involved in the canonical TGFβ/Smad signaling pathway to results from a clinical trial for patients with neuroendocrine tumors, a rare cancer type. Articles highlighted below are freely available for a limited time.Read More
In the past year, the number of American teenagers using tobacco products has increased by nearly 40 percent, reversing a trend that public health officials worked tirelessly to achieve.
The primary culprit in the resurgence of smoking? E-cigarettes. Taking aim at this growing public health problem, the American Association for Cancer Research (AACR) held a congressional briefing on Wednesday, June 12, titled “E-cigarettes and Nicotine Addiction: A Potential Health Crisis for Youth and Young Adults.” The roster of speakers included leaders from government, research, and policy sectors.
A recent estimate suggests that more than 40 percent of cancers could be prevented. Modifiable factors linked to cancer include tobacco use, obesity, alcohol consumption, and exposure to environmental carcinogens, which are substances in our surroundings that can cause cancer and may facilitate progression of the disease.
Environmental carcinogens could be present in our air, water, or food. While some of these carcinogens have been identified, scientists believe that current measures to mitigate our exposures are inadequate. Other carcinogens present in our environment have yet to be fully defined.
To address these issues, the AACR is hosting a conference focusing on Environmental Carcinogenesis: Potential Pathway to Cancer Prevention next week in Charlotte, North Carolina. This meeting will review current advances in the field with the goal of sparking ideas and discussion about novel ways to prevent cancer.Read More
The tobacco product landscape is evolving and the AACR Tobacco Products and Cancer Subcommittee has been cognizant of the shift from combusted products (e.g., cigarettes) to alternative nicotine delivery systems, such as e-cigarettes. While it is generally accepted that e-cigarettes are safer than traditional cigarettes, these products still present risks and the AACR has been active in trying to keep children from having access to them.Read More